Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Leukemia

  Free Subscription


Articles published in Bone Marrow Transplant

Retrieve available abstracts of 175 articles:
HTML format



Single Articles


    June 2022
  1. LAZZARI L, Balaguer-Rosello A, Montoro J, Greco R, et al
    Post-transplant cyclophosphamide and sirolimus based graft-versus-host disease prophylaxis after allogeneic stem cell transplantation for acute myeloid leukemia.
    Bone Marrow Transplant. 2022 Jun 9. pii: 10.1038/s41409-022-01725.
    PubMed     Abstract available


  2. OHMOTO A, Fuji S, Shultes KC, Savani BN, et al
    Controversies about immunoglobulin replacement therapy in HSCT recipients with hypogammaglobulinemia.
    Bone Marrow Transplant. 2022;57:874-880.
    PubMed     Abstract available


  3. KEVLICIUS L, Cepulyte R, Vasilevska D, Griskevicius L, et al
    Venetoclax-based regimens in combination with trametinib for RAS-mutated relapsed or refractory myeloid malignancies.
    Bone Marrow Transplant. 2022;57:1034-1037.
    PubMed    


  4. MAAKARON JE, Zhang MJ, Chen K, Abhyankar S, et al
    Age is no barrier for adults undergoing HCT for AML in CR1: contemporary CIBMTR analysis.
    Bone Marrow Transplant. 2022;57:911-917.
    PubMed     Abstract available


  5. ONIDA F, Sbianchi G, Radujkovic A, Sockel K, et al
    Prognostic value of a new clinically-based classification system in patients with CMML undergoing allogeneic HCT: a retrospective analysis of the EBMT-CMWP.
    Bone Marrow Transplant. 2022;57:896-902.
    PubMed     Abstract available


    May 2022
  6. GUIJARRO F, Bataller A, Diaz-Beya M, Garrido A, et al
    Long-term outcomes in patients with relapsed/refractory acute myeloid leukemia and other high-risk myeloid malignancies after undergoing sequential conditioning regimen based on IDA-FLAG and high-dose melphalan.
    Bone Marrow Transplant. 2022 May 28. pii: 10.1038/s41409-022-01703.
    PubMed     Abstract available


  7. DUQUE-AFONSO J, Finke J, Labopin M, Craddock C, et al
    Comparison of fludarabine-melphalan and fludarabine-treosulfan as conditioning prior to allogeneic hematopoietic cell transplantation-a registry study on behalf of the EBMT Acute Leukemia Working Party.
    Bone Marrow Transplant. 2022 May 14. pii: 10.1038/s41409-022-01646.
    PubMed     Abstract available


  8. DANYLESKO I, Peczynski C, Labopin M, Polge E, et al
    Impact of donor kinship on non-T-cell depleted haploidentical stem cell transplantation with post transplantation cyclophosphamide for acute leukemia: From the ALWP of the EBMT.
    Bone Marrow Transplant. 2022 May 13. pii: 10.1038/s41409-022-01695.
    PubMed     Abstract available


  9. YOKOYAMA H, Kanaya M, Iemura T, Hirayama M, et al
    Improved outcomes of single-unit cord blood transplantation for acute myeloid leukemia by killer immunoglobulin-like receptor 2DL1-ligand mismatch.
    Bone Marrow Transplant. 2022 May 10. pii: 10.1038/s41409-022-01700.
    PubMed     Abstract available


    April 2022
  10. NAGLER A, Peczynski C, Dholaria B, Labopin M, et al
    Impact of conditioning regimen intensity on outcomes of second allogeneic hematopoietic cell transplantation for secondary acute myelogenous leukemia.
    Bone Marrow Transplant. 2022 Apr 30. pii: 10.1038/s41409-022-01693.
    PubMed     Abstract available


  11. DELIA M, Carluccio P, Gagliardi VP, Mestice A, et al
    Deciphering the effects of graft Tregs on chronic graft-versus-host disease: results from a prospective, multicenter study in patients with acute leukemia undergoing allogeneic peripheral blood stem cell transplantation.
    Bone Marrow Transplant. 2022 Apr 19. pii: 10.1038/s41409-022-01676.
    PubMed    


  12. BONIFAZI F, Pavoni C, Peccatori J, Giglio F, et al
    Myeloablative conditioning with thiotepa-busulfan-fludarabine does not improve the outcome of patients transplanted with active leukemia: final results of the GITMO prospective trial GANDALF-01.
    Bone Marrow Transplant. 2022 Apr 12. pii: 10.1038/s41409-022-01626.
    PubMed     Abstract available


  13. RODRIGUEZ-ARBOLI E, Labopin M, Eder M, Brecht A, et al
    Augmented FLAMSA-Bu versus FluBu2 reduced-intensity conditioning in patients with active relapsed/refractory acute myeloid leukemia: an EBMT analysis.
    Bone Marrow Transplant. 2022 Apr 7. pii: 10.1038/s41409-022-01611.
    PubMed     Abstract available


  14. HAROON A, Alfraih F, Hanbali A, Kotb A, et al
    Allogeneic transplant compared to pediatric-inspired therapy for Philadelphia chromosome-negative adolescent and adult ALL in first complete remission.
    Bone Marrow Transplant. 2022;57:593-597.
    PubMed     Abstract available


  15. GALLI E, Metafuni E, Giammarco S, Limongiello MA, et al
    Triple post transplant cyclophosphamide (PTCY) based GVHD prophylaxis: HLA matched versus HLA haploidentical transplants.
    Bone Marrow Transplant. 2022;57:532-537.
    PubMed     Abstract available


    March 2022
  16. WANG L, Gao W, Wang L, Wan M, et al
    Cladribine-based debulking chemotherapy sequential with reduced intensity regimen and post-transplantation maintenance for refractory myeloid leukemia: a prospective phase II clinical trial.
    Bone Marrow Transplant. 2022 Mar 29. pii: 10.1038/s41409-022-01639.
    PubMed    


  17. JIANG JL, Chen M, Wang LN, Wan M, et al
    Double alkylators based conditioning reduced the relapse rate after allogeneic peripheral blood stem cell transplantation in adult patients with myeloid malignancies: a single arm phase II study.
    Bone Marrow Transplant. 2022 Mar 24. pii: 10.1038/s41409-022-01643.
    PubMed    


  18. OKADA Y, Nakasone H, Nakamura Y, Kawamura M, et al
    Prognostic impact of chromosomal changes at relapse after allogeneic hematopoietic cell transplantation for acute myeloid leukemia or myelodysplastic syndrome.
    Bone Marrow Transplant. 2022 Mar 21. pii: 10.1038/s41409-022-01635.
    PubMed     Abstract available


  19. JIMENEZ JIMENEZ AM, De Lima M, Komanduri KV, Wang TP, et al
    Correction to: An adapted European LeukemiaNet genetic risk stratification for acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplant. A CIBMTR analysis.
    Bone Marrow Transplant. 2022 Mar 16. pii: 10.1038/s41409-022-01625.
    PubMed    


  20. HERNANDEZ-BOLUDA JC, Pereira A, Zinger N, Gras L, et al
    Allogeneic hematopoietic cell transplantation in patients with myeloid/lymphoid neoplasm with FGFR1-rearrangement: a study of the Chronic Malignancies Working Party of EBMT.
    Bone Marrow Transplant. 2022;57:416-422.
    PubMed     Abstract available


  21. HAN S, Zhou L, Chen Y, Zhou X, et al
    The role of allogeneic haematopoietic cell transplantation as consolidation after anti-CD19 CAR-T cell therapy in adults with relapsed/refractory acute lymphoblastic leukaemia: a prospective cohort study.
    Bone Marrow Transplant. 2022;57:513-516.
    PubMed    


  22. FUJI S, Hirakawa T, Takano K, Doki N, et al
    Disease-specific impact of anti-thymocyte globulin in allogeneic hematopoietic cell transplantation: a nationwide retrospective study on behalf of the JSTCT, transplant complications working group.
    Bone Marrow Transplant. 2022;57:479-486.
    PubMed     Abstract available


    February 2022
  23. ZHANG Z, Hasegawa Y, Hashimoto D, Senjo H, et al
    Gilteritinib enhances graft-versus-leukemia effects against FLT3-ITD mutant leukemia after allogeneic hematopoietic stem cell transplantation.
    Bone Marrow Transplant. 2022 Feb 28. pii: 10.1038/s41409-022-01619.
    PubMed     Abstract available


  24. LINDAHL H, Vonlanthen S, Valentini D, Bjorklund AT, et al
    Lineage-specific early complete donor chimerism and risk of relapse after allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia.
    Bone Marrow Transplant. 2022 Feb 24. pii: 10.1038/s41409-022-01615.
    PubMed     Abstract available


  25. CANDONI A, Lazzarotto D, Rambaldi A, Dubbini MV, et al
    Effect of prophylactic or pre-emptive use of tyrosine kinase inhibitors post-Allo SCT in bcr-abl positive acute lymphoblastic leukemia: a subanalysis of GITMO ph-positive ALL study.
    Bone Marrow Transplant. 2022 Feb 24. pii: 10.1038/s41409-022-01618.
    PubMed    


  26. PIEMONTESE S, Lazzari L, Ruggeri A, Marcatti M, et al
    Allogeneic hematopoietic stem cell transplantation in patients older than 65 years with acute myeloid leukemia and myelodysplastic syndrome: a 15-year experience.
    Bone Marrow Transplant. 2022 Feb 5. pii: 10.1038/s41409-022-01600.
    PubMed    


  27. NAGLER A, Labopin M, Huang XJ, Blaise D, et al
    Non-T depleted haploidentical stem cell transplantation in AML patients achieving first complete remission after one versus two induction courses: a study from the ALWP/EBMT.
    Bone Marrow Transplant. 2022 Feb 1. pii: 10.1038/s41409-021-01537.
    PubMed     Abstract available


  28. YEH AC, O'Donnell PV, Schoch G, Martin PJ, et al
    Long-term survival with mixed chimerism in patients with AML and MDS transplanted after conditioning with targeted busulfan, fludarabine, and thymoglobulin.
    Bone Marrow Transplant. 2022;57:198-206.
    PubMed     Abstract available


  29. POLLYEA DA, Winters A, McMahon C, Schwartz M, et al
    Venetoclax and azacitidine followed by allogeneic transplant results in excellent outcomes and may improve outcomes versus maintenance therapy among newly diagnosed AML patients older than 60.
    Bone Marrow Transplant. 2022;57:160-166.
    PubMed     Abstract available


    January 2022
  30. BATTIPAGLIA G, Galimard JE, Labopin M, Raiola AM, et al
    Post-transplant cyclophosphamide in one-antigen mismatched unrelated donor transplantation versus haploidentical transplantation in acute myeloid leukemia: a study from the Acute Leukemia Working Party of the EBMT.
    Bone Marrow Transplant. 2022 Jan 25. pii: 10.1038/s41409-022-01577.
    PubMed     Abstract available


  31. NI F, Yin ETS, Zhou L, Zhao H, et al
    Outcomes of CD19 chimeric antigen receptor T cell followed by haploidentical hematopoietic stem-cell transplantation in relapsed/refractory B-cell acute lymphoblastic leukemia with IKZF1 deletion.
    Bone Marrow Transplant. 2022 Jan 24. pii: 10.1038/s41409-021-01554.
    PubMed    


  32. UTSUNOMIYA A, Tokunaga M, Nakano N, Fujiwara H, et al
    Long-term follow-up of patients with ATL after autologous stem cell transplantation.
    Bone Marrow Transplant. 2022 Jan 23. pii: 10.1038/s41409-021-01412.
    PubMed    


  33. SWOBODA R, Labopin M, Giebel S, Angelucci E, et al
    Total body irradiation plus fludarabine versus thiotepa, busulfan plus fludarabine as a myeloablative conditioning for adults with acute lymphoblastic leukemia treated with haploidentical hematopoietic cell transplantation. A study by the Acute Leukem
    Bone Marrow Transplant. 2022 Jan 15. pii: 10.1038/s41409-021-01550.
    PubMed     Abstract available


  34. SHIMONI A
    Relapse of acute leukemia after a second allogeneic stem- cell transplantation; Is there any hope for cure?
    Bone Marrow Transplant. 2022 Jan 14. pii: 10.1038/s41409-021-01508.
    PubMed    


  35. SHIMONI A, Labopin M, Angelucci E, Blaise D, et al
    The association of graft-versus-leukemia effect and graft-versus host disease in haploidentical transplantation with post-transplant cyclophosphamide for AML.
    Bone Marrow Transplant. 2022 Jan 13. pii: 10.1038/s41409-021-01493.
    PubMed     Abstract available


  36. EL HUSSEIN S, DiNardo CD, Takahashi K, Khoury JD, et al
    Acquired WT1 mutations contribute to relapse of NPM1-mutated acute myeloid leukemia following allogeneic hematopoietic stem cell transplant.
    Bone Marrow Transplant. 2022 Jan 7. pii: 10.1038/s41409-021-01538.
    PubMed     Abstract available


  37. ANDOLINA JR, Wang YC, Ji L, Freyer DR, et al
    Adolescent and young adult (AYA) versus pediatric patients with acute leukemia have a significantly increased risk of acute GVHD following unrelated donor (URD) stem cell transplantation (SCT): the Children's Oncology Group experience.
    Bone Marrow Transplant. 2022 Jan 6. pii: 10.1038/s41409-021-01558.
    PubMed     Abstract available


  38. KANDA J, Hayashi H, Ruggeri A, Kimura F, et al
    The impact of GVHD on outcomes after adult single cord blood transplantation in European and Japanese populations.
    Bone Marrow Transplant. 2022;57:57-64.
    PubMed     Abstract available


  39. CAI J, Kim S
    Case-cohort design in hematopoietic cell transplant studies.
    Bone Marrow Transplant. 2022;57:1-5.
    PubMed     Abstract available


    December 2021
  40. BETHGE WA, Eyrich M, Mielke S, Meisel R, et al
    Results of a multicenter phase I/II trial of TCRalphabeta and CD19-depleted haploidentical hematopoietic stem cell transplantation for adult and pediatric patients.
    Bone Marrow Transplant. 2021 Dec 24. pii: 10.1038/s41409-021-01551.
    PubMed     Abstract available


  41. LIANG EC, Chen C, Lu R, Mannis GN, et al
    Measurable residual disease status and FLT3 inhibitor therapy in patients with FLT3-ITD mutated AML following allogeneic hematopoietic cell transplantation.
    Bone Marrow Transplant. 2021;56:3091-3093.
    PubMed     Abstract available


  42. KUROSAWA S, Shimomura Y, Itonaga H, Najima Y, et al
    Fludarabine/busulfan versus busulfan/cyclophosphamide as myeloablative conditioning for myelodysplastic syndrome: a propensity score-matched analysis.
    Bone Marrow Transplant. 2021;56:3008-3015.
    PubMed     Abstract available


  43. SHARMA A, Huang S, Li Y, Brooke RJ, et al
    Outcomes of pediatric patients with therapy-related myeloid neoplasms.
    Bone Marrow Transplant. 2021;56:2997-3007.
    PubMed     Abstract available


    November 2021
  44. SHUMILOV E, Shakhanova I, Flach J, Schmidt N, et al
    Feasibility and efficacy of salvage allogeneic stem cell transplantation in AML patients relapsing after autologous stem cell transplantation.
    Bone Marrow Transplant. 2021 Nov 13. pii: 10.1038/s41409-021-01521.
    PubMed     Abstract available


  45. SCHETELIG J, Hoek J, Stilgenbauer S, Middeke JM, et al
    Correction to: Allogeneic hematopoietic cell transplantation for patients with TP53 mutant or deleted chronic lymphocytic leukemia: results of a prospective observational study.
    Bone Marrow Transplant. 2021 Nov 12. pii: 10.1038/s41409-021-01524.
    PubMed    


  46. SCHETELIG J, Chevallier P, van Gelder M, Hoek J, et al
    Correction to: Idelalisib treatment prior to allogeneic stem cell transplantation for patients with chronic lymphocytic leukemia: a report from the EBMT chronic malignancies working party.
    Bone Marrow Transplant. 2021 Nov 12. pii: 10.1038/s41409-021-01516.
    PubMed    


  47. SCHMID C, Labopin M, Schaap N, Veelken H, et al
    Long-term results and GvHD after prophylactic and preemptive donor lymphocyte infusion after allogeneic stem cell transplantation for acute leukemia.
    Bone Marrow Transplant. 2021 Nov 8. pii: 10.1038/s41409-021-01515.
    PubMed     Abstract available


  48. MOHTY R, Gauthier J
    Current combinatorial CAR T cell strategies with Bruton tyrosine kinase inhibitors and immune checkpoint inhibitors.
    Bone Marrow Transplant. 2021;56:2630-2636.
    PubMed     Abstract available


  49. BARON F, Ngoya M, Labopin M, Cornelissen JJ, et al
    Comparison of long-term outcome for AML patients alive free of disease 2 years after allogeneic hematopoietic cell transplantation with umbilical cord blood versus unrelated donor: a study from the ALWP of the EBMT.
    Bone Marrow Transplant. 2021;56:2742-2748.
    PubMed     Abstract available


  50. KRIEGER E, Qayyum R, Keating A, Toor A, et al
    Increased donor inhibitory KIR with known HLA interactions provide protection from relapse following HLA matched unrelated donor HCT for AML.
    Bone Marrow Transplant. 2021;56:2714-2722.
    PubMed     Abstract available


    October 2021
  51. TIEN FM, Tsai CH, Huang SC, Liu JH, et al
    Distinct clinico-biological features in AML patients with low allelic ratio FLT3-ITD: role of allogeneic stem cell transplantation in first remission.
    Bone Marrow Transplant. 2021 Oct 20. pii: 10.1038/s41409-021-01454.
    PubMed     Abstract available


  52. BAZARBACHI A
    Exciting times ahead for older patients with acute myeloid leukemia: azacitidine and venetoclax followed by allogeneic hematopoietic cell transplantation.
    Bone Marrow Transplant. 2021 Oct 13. pii: 10.1038/s41409-021-01474.
    PubMed    


  53. YANADA M, Ota S, Mukae J, Nara M, et al
    Autologous hematopoietic cell transplantation during second or subsequent complete remission of acute promyelocytic leukemia: a prognostic factor analysis.
    Bone Marrow Transplant. 2021 Oct 13. pii: 10.1038/s41409-021-01501.
    PubMed     Abstract available


  54. KOBAYASHI S, Kanda Y, Konuma T, Inamoto Y, et al
    Outcomes of third allogeneic hematopoietic stem cell transplantation in relapsed/refractory acute leukemia after a second transplantation.
    Bone Marrow Transplant. 2021 Oct 8. pii: 10.1038/s41409-021-01485.
    PubMed     Abstract available


  55. POIRE X, Graux C, Ory A, Herman J, et al
    Sequential administration of low dose 5-azacytidine (AZA) and donor lymphocyte infusion (DLI) for patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) in relapse after allogeneic stem cell transplantation (SCT): a prospective s
    Bone Marrow Transplant. 2021 Oct 5. pii: 10.1038/s41409-021-01464.
    PubMed    


  56. MASOURIDI-LEVRAT S, Olavarria E, Iacobelli S, Aljurf M, et al
    Outcomes and toxicity of allogeneic hematopoietic cell transplantation in chronic myeloid leukemia patients previously treated with second-generation tyrosine kinase inhibitors: a prospective non-interventional study from the Chronic Malignancy Workin
    Bone Marrow Transplant. 2021 Oct 1. pii: 10.1038/s41409-021-01472.
    PubMed     Abstract available


    September 2021
  57. JIMENEZ JIMENEZ AM, De Lima M, Komanduri KV, Wang TP, et al
    An adapted European LeukemiaNet genetic risk stratification for acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplant. A CIBMTR analysis.
    Bone Marrow Transplant. 2021 Sep 28. pii: 10.1038/s41409-021-01450.
    PubMed     Abstract available


  58. HU K, Wang Y, Teng X, Hu Y, et al
    Cell subsets and cytokine dynamics in cerebrospinal fluid after CAR-T cell therapy for B-cell acute lymphoblastic leukemia with central nervous system involvement.
    Bone Marrow Transplant. 2021 Sep 27. pii: 10.1038/s41409-021-01471.
    PubMed    


  59. YOKOYAMA H, Hirayama M, Takahashi Y, Uchida N, et al
    Altered effect of killer immunoglobulin-like receptor-ligand mismatch by graft versus host disease prophylaxis in cord blood transplantation.
    Bone Marrow Transplant. 2021 Sep 24. pii: 10.1038/s41409-021-01469.
    PubMed     Abstract available


  60. ROCHA V, Arcuri LJ, Seber A, Colturato V, et al
    Impact of mother donor, peripheral blood stem cells and measurable residual disease on outcomes after haploidentical hematopoietic cell transplantation with post-transplant cyclophosphamide in children with acute leukaemia.
    Bone Marrow Transplant. 2021 Sep 21. pii: 10.1038/s41409-021-01453.
    PubMed     Abstract available


  61. PINCEZ T, Santiago R, Bittencourt H, Louis I, et al
    Intensive monitoring of minimal residual disease and chimerism after allogeneic hematopoietic stem cell transplantation for acute leukemia in children.
    Bone Marrow Transplant. 2021 Sep 2. pii: 10.1038/s41409-021-01408.
    PubMed     Abstract available


  62. PHAM B, Hoeg R, Krishnan R, Richman C, et al
    Safety and tolerability of lenalidomide maintenance in post-transplant acute myeloid leukemia and high-risk myelodysplastic syndrome.
    Bone Marrow Transplant. 2021 Sep 1. pii: 10.1038/s41409-021-01444.
    PubMed     Abstract available


  63. GALE RP, Schiffer CA, Lazarus HM
    Granulocyte transfusions in haematopoietic cell transplants and leukaemia: the phoenix or beating a dead horse?
    Bone Marrow Transplant. 2021;56:2046-2049.
    PubMed    


    August 2021
  64. INOUE Y, Nakano N, Fuji S, Eto T, et al
    Impact of conditioning intensity and regimen on transplant outcomes in patients with adult T-cell leukemia-lymphoma.
    Bone Marrow Transplant. 2021 Aug 31. pii: 10.1038/s41409-021-01445.
    PubMed     Abstract available


  65. XU LP, Lu PH, Wu DP, Sun ZM, et al
    Hematopoietic stem cell transplantation activity in China 2019: a report from the Chinese Blood and Marrow Transplantation Registry Group.
    Bone Marrow Transplant. 2021 Aug 25. pii: 10.1038/s41409-021-01431.
    PubMed     Abstract available


  66. TAMAI H, Tajika K, Nakayama K, Arai A, et al
    Treatment of relapsed aggressive adult T-cell leukemia/lymphoma after allogeneic hematopoietic stem cell transplantation with mogamulizumab followed by lenalidomide.
    Bone Marrow Transplant. 2021 Aug 12. pii: 10.1038/s41409-021-01432.
    PubMed    


  67. ABOU DALLE I, Bazarbachi A
    Successful venetoclax and Actinomycin D-based treatment for relapsed acute myeloid leukemia post allogeneic hematopoietic cell transplantation.
    Bone Marrow Transplant. 2021 Aug 10. pii: 10.1038/s41409-021-01434.
    PubMed    


  68. CRUIJSEN M, Hilberink JR, van der Velden WJFM, Jansen JH, et al
    Low relapse risk in poor risk AML after conditioning with 10-day decitabine, fludarabine and 2 Gray TBI prior to allogeneic hematopoietic cell transplantation.
    Bone Marrow Transplant. 2021;56:1964-1970.
    PubMed     Abstract available


  69. RUGGERI L, Vago L, Eikema DJ, de Wreede LC, et al
    Natural killer cell alloreactivity in HLA-haploidentical hematopoietic transplantation: a study on behalf of the CTIWP of the EBMT.
    Bone Marrow Transplant. 2021;56:1900-1907.
    PubMed     Abstract available


    July 2021
  70. AKAHOSHI Y, Arai Y, Nishiwaki S, Tachibana T, et al
    Newly proposed threshold and validation of white blood cell count at diagnosis for Philadelphia chromosome-positive acute lymphoblastic leukemia: risk assessment of relapse in patients with negative minimal residual disease at transplantation-a report
    Bone Marrow Transplant. 2021 Jul 30. pii: 10.1038/s41409-021-01422.
    PubMed     Abstract available


  71. NIEDERWIESER C, Morozova E, Zubarovskaya L, Zabelina T, et al
    Risk factors for outcome after allogeneic stem cell transplantation in patients with advanced phase CML.
    Bone Marrow Transplant. 2021 Jul 30. pii: 10.1038/s41409-021-01410.
    PubMed     Abstract available


  72. ZUCENKA A, Vaitekenaite V, Maneikis K, Davainis L, et al
    Venetoclax-based salvage therapy followed by Venetoclax and DLI maintenance vs. FLAG-Ida for relapsed or refractory acute myeloid leukemia after allogeneic stem cell transplantation.
    Bone Marrow Transplant. 2021 Jul 17. pii: 10.1038/s41409-021-01416.
    PubMed     Abstract available


  73. KONUMA T, Kondo T, Masuko M, Shimizu H, et al
    Prognostic value of measurable residual disease at allogeneic transplantation for adults with core binding factor acute myeloid leukemia in complete remission.
    Bone Marrow Transplant. 2021 Jul 16. pii: 10.1038/s41409-021-01409.
    PubMed     Abstract available


  74. JENTZSCH M, Grimm J, Bill M, Kupper J, et al
    Measurable residual disease of canonical versus non-canonical DNMT3A, TET2, or ASXL1 mutations in AML at stem cell transplantation.
    Bone Marrow Transplant. 2021 Jul 15. pii: 10.1038/s41409-021-01407.
    PubMed    


  75. GREIL C, Engelhardt M, Ihorst G, Duque-Afonso J, et al
    Correction to: Prognostic factors for survival after allogeneic transplantation in acute lymphoblastic leukemia.
    Bone Marrow Transplant. 2021 Jul 8. pii: 10.1038/s41409-021-01366.
    PubMed    


    June 2021
  76. GEVA M, Pryce A, Shouval R, Fein JA, et al
    High lactate dehydrogenase at time of admission for allogeneic hematopoietic transplantation associates to poor survival in acute myeloid leukemia and non-Hodgkin lymphoma.
    Bone Marrow Transplant. 2021 Jun 29. pii: 10.1038/s41409-021-01377.
    PubMed     Abstract available


  77. CHO BS, Min GJ, Park SS, Park S, et al
    Prognostic values of D816V KIT mutation and peri-transplant CBFB-MYH11 MRD monitoring on acute myeloid leukemia with CBFB-MYH11.
    Bone Marrow Transplant. 2021 Jun 28. pii: 10.1038/s41409-021-01384.
    PubMed     Abstract available


  78. SHIMOMURA Y, Hara M, Hirabayashi S, Kondo T, et al
    Comparison of fludarabine, a myeloablative dose of busulfan, and melphalan vs conventional myeloablative conditioning regimen in patients with relapse and refractory acute myeloid leukemia in non-remission status.
    Bone Marrow Transplant. 2021 Jun 21. pii: 10.1038/s41409-021-01380.
    PubMed    


  79. BRUZZESE A, Assanto GM, Diverio D, Quattrocchi L, et al
    Pre-emptive use of Sorafenib combined with DLI post HSCT in AML FLT3+: a single center experience.
    Bone Marrow Transplant. 2021;56:1455-1457.
    PubMed    


    May 2021
  80. WAIDHAUSER J, Labopin M, Esteve J, Kroger N, et al
    Allogeneic stem cell transplantation for AML patients with RUNX1 mutation in first complete remission: a study on behalf of the acute leukemia working party of the EBMT.
    Bone Marrow Transplant. 2021 May 31. pii: 10.1038/s41409-021-01322.
    PubMed     Abstract available


  81. MIKULSKA M, Tridello G, Hoek J, Gil L, et al
    Legionellosis after hematopoietic stem cell transplantation.
    Bone Marrow Transplant. 2021 May 22. pii: 10.1038/s41409-021-01333.
    PubMed     Abstract available


  82. PERCIVAL ME, Wang HL, Zhang MJ, Saber W, et al
    Correction to: Impact of depth of clinical response on outcomes of acute myeloid leukemia patients in first complete remission who undergo allogeneic hematopoietic cell transplantation.
    Bone Marrow Transplant. 2021 May 20. pii: 10.1038/s41409-021-01353.
    PubMed    


  83. BEAUVERD Y, Morin S, Stephan C, De Ramon Ortiz C, et al
    The EBMT Cytogenetic Risk Score maintains its prognostic significance in acute myeloid leukemia following allogeneic stem cell transplantation in a cohort with 40% of patients transplanted with in vitro partial T-cell depleted graft.
    Bone Marrow Transplant. 2021 May 18. pii: 10.1038/s41409-021-01334.
    PubMed    


  84. KANAAN SB, Delaney C, Milano F, Scaradavou A, et al
    Cord blood maternal microchimerism following unrelated cord blood transplantation.
    Bone Marrow Transplant. 2021;56:1090-1098.
    PubMed     Abstract available


  85. QIAN CS, Ma X, Wang J, Wang TJ, et al
    PD1 inhibitor in combination with 5-azacytidine and low-dose DLI for the successful treatment of AML patients who relapsed after transplantation.
    Bone Marrow Transplant. 2021;56:1003-1005.
    PubMed    


    April 2021
  86. KHARFAN-DABAJA MA, Labopin M, Bazarbachi A, Ciceri F, et al
    Comparing outcomes of a second allogeneic hematopoietic cell transplant using HLA-matched unrelated versus T-cell replete haploidentical donors in relapsed acute lymphoblastic leukemia: a study of the Acute Leukemia Working Party of EBMT.
    Bone Marrow Transplant. 2021 Apr 30. pii: 10.1038/s41409-021-01317.
    PubMed     Abstract available


  87. TOYODA K, Yasunaga JI, Choi I, Suehiro Y, et al
    The HTLV-1 proviral status is a potential prognostic biomarker for adult T-cell leukemia-lymphoma treated with allogeneic stem cell transplantation.
    Bone Marrow Transplant. 2021 Apr 29. pii: 10.1038/s41409-021-01311.
    PubMed    


  88. RAGON BK
    FLT3-ITDos and FLT3-ITDon'ts: navigating maintenance therapy in FLT3-ITD-positive acute myeloid leukemia following stem cell transplantation.
    Bone Marrow Transplant. 2021 Apr 28. pii: 10.1038/s41409-021-01269.
    PubMed    


  89. RUSSO D, Polverelli N, Malagola M, Farina M, et al
    Changes in Stem Cell Transplant activity and procedures during SARS-CoV2 pandemic in Italy: an Italian Bone Marrow Transplant Group (GITMO) nationwide analysis (TransCOVID-19 Survey).
    Bone Marrow Transplant. 2021 Apr 19. pii: 10.1038/s41409-021-01287.
    PubMed     Abstract available


  90. PERCIVAL ME, Wang HL, Zhang MJ, Saber W, et al
    Impact of depth of clinical response on outcomes of acute myeloid leukemia patients in first complete remission who undergo allogeneic hematopoietic cell transplantation.
    Bone Marrow Transplant. 2021 Apr 16. pii: 10.1038/s41409-021-01261.
    PubMed     Abstract available


  91. BADAR T, Szabo A, Litzow M, Burkart M, et al
    Multi-institutional study evaluating clinical outcome with allogeneic hematopoietic stem cell transplantation after blinatumomab in patients with B-cell acute lymphoblastic leukemia: real-world data.
    Bone Marrow Transplant. 2021 Apr 6. pii: 10.1038/s41409-021-01279.
    PubMed     Abstract available


  92. CHO H, Kim Y, Yoon JH, Lee J, et al
    Non-inferior long-term outcomes of adults with Philadelphia chromosome-like acute lymphoblastic leukemia.
    Bone Marrow Transplant. 2021 Apr 6. pii: 10.1038/s41409-021-01253.
    PubMed     Abstract available


    March 2021
  93. KOLLER P, Saliba RM, Ledesma C, Rondon G, et al
    Outcomes in patients with CRLF2 overexpressed acute lymphoblastic leukemia after allogeneic hematopoietic cell transplantation.
    Bone Marrow Transplant. 2021 Mar 25. pii: 10.1038/s41409-021-01262.
    PubMed    


  94. DAHER-REYES G, Kim T, Novitzky-Basso I, Kim KH, et al
    Prognostic impact of the adverse molecular-genetic profile on long-term outcomes following allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia.
    Bone Marrow Transplant. 2021 Mar 25. pii: 10.1038/s41409-021-01255.
    PubMed     Abstract available


  95. SHARMA A, Li Y, Huang S, Talleur AC, et al
    Outcomes of pediatric patients who relapse after first HCT for acute leukemia or MDS.
    Bone Marrow Transplant. 2021 Mar 19. pii: 10.1038/s41409-021-01267.
    PubMed     Abstract available


  96. VERSLUYS AB, Boelens JJ, Pronk C, Lankester A, et al
    Correction: Hematopoietic cell transplant in pediatric acute myeloid leukemia after similar upfront therapy; a comparison of conditioning regimens.
    Bone Marrow Transplant. 2021 Mar 15. pii: 10.1038/s41409-021-01257.
    PubMed    


  97. SAKAGUCHI H, Miyamura T, Tomizawa D, Taga T, et al
    Effect of extramedullary disease on allogeneic hematopoietic cell transplantation for pediatric acute myeloid leukemia: a nationwide retrospective study.
    Bone Marrow Transplant. 2021 Mar 10. pii: 10.1038/s41409-021-01250.
    PubMed     Abstract available


  98. WILLIAMS L, Doucette K, Karp JE, Lai C, et al
    Genetics of donor cell leukemia in acute myelogenous leukemia and myelodysplastic syndrome.
    Bone Marrow Transplant. 2021 Mar 8. pii: 10.1038/s41409-021-01214.
    PubMed     Abstract available


  99. YANADA M
    The evolving concept of indications for allogeneic hematopoietic cell transplantation during first complete remission of acute myeloid leukemia.
    Bone Marrow Transplant. 2021 Mar 8. pii: 10.1038/s41409-021-01247.
    PubMed     Abstract available


  100. RUGGERI A, Labopin M, Angelucci E, Blaise D, et al
    Prognostic factors for neutrophil engraftment after haploidentical cell transplantation with PT-Cy in patients with acute myeloid leukemia in complete remission, on behalf of the ALWP-EBMT.
    Bone Marrow Transplant. 2021 Mar 5. pii: 10.1038/s41409-021-01248.
    PubMed     Abstract available


    February 2021
  101. TANG X, Valdez BC, Ma Y, Zhang Q, et al
    Low-dose decitabine as part of a modified Bu-Cy conditioning regimen improves survival in AML patients with active disease undergoing allogeneic hematopoietic stem cell transplantation.
    Bone Marrow Transplant. 2021 Feb 26. pii: 10.1038/s41409-021-01238.
    PubMed     Abstract available


  102. QU C, Song Y, Yin J, Ma Y, et al
    Decitabine may improve CAR-T efficacy in refractory/relapsed acute leukemia patients carrying TP53 alterations.
    Bone Marrow Transplant. 2021 Feb 24. pii: 10.1038/s41409-021-01230.
    PubMed    


  103. DUNAIKINA M, Zhekhovtsova Z, Shelikhova L, Glushkova S, et al
    Safety and efficacy of the low-dose memory (CD45RA-depleted) donor lymphocyte infusion in recipients of alphabeta T cell-depleted haploidentical grafts: results of a prospective randomized trial in high-risk childhood leukemia.
    Bone Marrow Transplant. 2021 Feb 16. pii: 10.1038/s41409-021-01232.
    PubMed     Abstract available


  104. CHRISTOPEIT M, Reichard M, Niederwieser C, Massoud R, et al
    Allogeneic stem cell transplantation in acute leukemia patients after COVID-19 infection.
    Bone Marrow Transplant. 2021 Feb 9. pii: 10.1038/s41409-021-01225.
    PubMed    


  105. PAUTAS C, Raffoux E, Lambert J, Legrand O, et al
    Outcomes following hematopoietic stem cell transplantation in patients treated with standard chemotherapy with or without gemtuzumab ozogamicin for acute myeloid leukemia.
    Bone Marrow Transplant. 2021 Feb 9. pii: 10.1038/s41409-020-01207.
    PubMed     Abstract available


  106. RAUTENBERG C, Bergmann A, Pechtel S, Fischermanns C, et al
    Wilm's Tumor 1-guided preemptive treatment with hypomethylating agents for molecular relapse of AML and MDS after allogeneic transplantation.
    Bone Marrow Transplant. 2021;56:442-450.
    PubMed     Abstract available


  107. DEYA-MARTINEZ A, Alonso-Saladrigues A, Garcia AP, Faura A, et al
    Kinetics of humoral deficiency in CART19-treated children and young adults with acute lymphoblastic leukaemia.
    Bone Marrow Transplant. 2021;56:376-386.
    PubMed     Abstract available


    January 2021
  108. VERSLUYS AB, Boelens JJ, Pronk C, Lankester A, et al
    Hematopoietic cell transplant in pediatric acute myeloid leukemia after similar upfront therapy; a comparison of conditioning regimens.
    Bone Marrow Transplant. 2021 Jan 19. pii: 10.1038/s41409-020-01201.
    PubMed     Abstract available


  109. LOPEZ R, Plat G, Bertrand Y, Ducassou S, et al
    Testosterone deficiency in men surviving childhood acute leukemia after treatment with hematopoietic stem cell transplantation or testicular radiation: an L.E.A. study.
    Bone Marrow Transplant. 2021 Jan 16. pii: 10.1038/s41409-020-01180.
    PubMed     Abstract available


  110. NAKASONE H, Kako S, Mori T, Takahashi S, et al
    Stopping tyrosine kinase inhibitors started after allogeneic HCT in patients with Philadelphia chromosome-positive leukemia.
    Bone Marrow Transplant. 2021 Jan 8. pii: 10.1038/s41409-020-01206.
    PubMed     Abstract available


  111. YOKOYAMA H, Kanda J, Kawahara Y, Uchida N, et al
    Reduced leukemia relapse through cytomegalovirus reactivation in killer cell immunoglobulin-like receptor-ligand-mismatched cord blood transplantation.
    Bone Marrow Transplant. 2021 Jan 8. pii: 10.1038/s41409-020-01203.
    PubMed     Abstract available


    December 2020
  112. SANZ J, Labopin M, Sanz MA, Aljurf M, et al
    Hematopoietic stem cell transplantation for adults with relapsed acute promyelocytic leukemia in second complete remission.
    Bone Marrow Transplant. 2020 Dec 15. pii: 10.1038/s41409-020-01162.
    PubMed     Abstract available


  113. HIRSCHBUHL K, Labopin M, Houhou M, Gabellier L, et al
    Second- and third-generation tyrosine kinase inhibitors for Philadelphia-positive adult acute lymphoblastic leukemia relapsing post allogeneic stem cell transplantation-a registry study on behalf of the EBMT Acute Leukemia Working Party.
    Bone Marrow Transplant. 2020 Dec 9. pii: 10.1038/s41409-020-01173.
    PubMed     Abstract available


  114. MAZIARZ RT, Levis M, Patnaik MM, Scott BL, et al
    Midostaurin after allogeneic stem cell transplant in patients with FLT3-internal tandem duplication-positive acute myeloid leukemia.
    Bone Marrow Transplant. 2020 Dec 7. pii: 10.1038/s41409-020-01153.
    PubMed     Abstract available


  115. AHN JS, Kim T, Jung SH, Ahn SY, et al
    Allogeneic transplant can abrogate the risk of relapse in the patients of first remission acute myeloid leukemia with detectable measurable residual disease by next-generation sequencing.
    Bone Marrow Transplant. 2020 Dec 5. pii: 10.1038/s41409-020-01165.
    PubMed     Abstract available


  116. YANADA M, Konuma T, Yamasaki S, Kondo T, et al
    Relapse of acute myeloid leukemia after allogeneic hematopoietic cell transplantation: clinical features and outcomes.
    Bone Marrow Transplant. 2020 Dec 2. pii: 10.1038/s41409-020-01163.
    PubMed     Abstract available


    November 2020
  117. PAVIGLIANITI A, Labopin M, Blaise D, Socie G, et al
    Comparison of mycophenolate mofetil and calcineurin inhibitor versus calcineurin inhibitor-based graft-versus-host-disease prophylaxis for matched unrelated donor transplant in acute myeloid leukemia. A study from the ALWP of the EBMT.
    Bone Marrow Transplant. 2020 Nov 28. pii: 10.1038/s41409-020-01155.
    PubMed     Abstract available


  118. GIEBEL S, Labopin M, Socie G, Beauvais D, et al
    Allogeneic HCT for adults with B-cell precursor acute lymphoblastic leukemia harboring IKZF1 gene mutations. A study by the Acute Leukemia Working Party of the EBMT.
    Bone Marrow Transplant. 2020 Nov 25. pii: 10.1038/s41409-020-01139.
    PubMed     Abstract available


  119. HUA J, Zhang J, Zhang X, Wu X, et al
    Donor-derived anti-CD19 CAR T cells compared with donor lymphocyte infusion for recurrent B-ALL after allogeneic hematopoietic stem cell transplantation.
    Bone Marrow Transplant. 2020 Nov 24. pii: 10.1038/s41409-020-01140.
    PubMed     Abstract available


  120. JENTZSCH M, Grimm J, Bill M, Brauer D, et al
    ELN risk stratification and outcomes in secondary and therapy-related AML patients consolidated with allogeneic stem cell transplantation.
    Bone Marrow Transplant. 2020 Nov 19. pii: 10.1038/s41409-020-01129.
    PubMed     Abstract available


  121. BAZARBACHI AH, Al Hamed R, Labopin M, Halaburda K, et al
    Underdiagnosed veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS) as a major cause of multi-organ failure in acute leukemia transplant patients: an analysis from the EBMT Acute Leukemia Working Party.
    Bone Marrow Transplant. 2020 Nov 18. pii: 10.1038/s41409-020-01135.
    PubMed     Abstract available


  122. KANG HM, Kim SK, Lee JW, Chung NG, et al
    Efficacy of low dose antithymocyte globulin on overall survival, relapse rate, and infectious complications following allogeneic peripheral blood stem cell transplantation for leukemia in children.
    Bone Marrow Transplant. 2020 Nov 17. pii: 10.1038/s41409-020-01121.
    PubMed     Abstract available


    October 2020
  123. GREIL C, Engelhardt M, Ihorst G, Duque-Afonso J, et al
    Prognostic factors for survival after allogeneic transplantation in acute lymphoblastic leukemia.
    Bone Marrow Transplant. 2020 Oct 31. pii: 10.1038/s41409-020-01101.
    PubMed     Abstract available


  124. YOON JH, Min GJ, Park SS, Park S, et al
    Impact of donor type on long-term graft-versus-host disease-free/relapse-free survival for adult acute lymphoblastic leukemia in first remission.
    Bone Marrow Transplant. 2020 Oct 30. pii: 10.1038/s41409-020-01097.
    PubMed     Abstract available


  125. YANG L, Tan Y, Shi J, Zhao Y, et al
    Prophylactic modified donor lymphocyte infusion after low-dose ATG-F-based haploidentical HSCT with myeloablative conditioning in high-risk acute leukemia: a matched-pair analysis.
    Bone Marrow Transplant. 2020 Oct 19. pii: 10.1038/s41409-020-01088.
    PubMed     Abstract available


  126. BAZARBACHI A, Labopin M, Blaise D, Forcade E, et al
    Comparable outcomes of haploidentical transplant with TBF conditioning versus matched unrelated donor with fludarabine/busulfan conditioning for acute myeloid leukemia.
    Bone Marrow Transplant. 2020 Oct 6. pii: 10.1038/s41409-020-01074.
    PubMed     Abstract available


  127. SCHETELIG J, Chevallier P, van Gelder M, Hoek J, et al
    Idelalisib treatment prior to allogeneic stem cell transplantation for patients with chronic lymphocytic leukemia: a report from the EBMT chronic malignancies working party.
    Bone Marrow Transplant. 2020 Oct 2. pii: 10.1038/s41409-020-01069.
    PubMed     Abstract available


  128. LOKE J, Labopin M, Craddock C, Niederwieser D, et al
    Impact of patient: donor HLA disparity on reduced-intensity-conditioned allogeneic stem cell transplants from HLA mismatched unrelated donors for AML: from the ALWP of the EBMT.
    Bone Marrow Transplant. 2020 Oct 2. pii: 10.1038/s41409-020-01072.
    PubMed     Abstract available


    September 2020
  129. SAGLIO F, Berger M, Spadea M, Pessolano R, et al
    Haploidentical HSCT with post transplantation cyclophosphamide versus unrelated donor HSCT in pediatric patients affected by acute leukemia.
    Bone Marrow Transplant. 2020 Sep 23. pii: 10.1038/s41409-020-01063.
    PubMed     Abstract available


  130. DI CRISTANZIANO V, Meyer-Schwickerath C, Eberhardt KA, Rybniker J, et al
    Detection of SARS-CoV-2 viremia before onset of COVID-19 symptoms in an allo-transplanted patient with acute leukemia.
    Bone Marrow Transplant. 2020 Sep 18. pii: 10.1038/s41409-020-01059.
    PubMed    


  131. ZAMPERLINI-NETTO G, Fernandes JF, Garcia JL, Ribeiro AAF, et al
    COVID-19 after hematopoietic stem cell transplantation: report of two children.
    Bone Marrow Transplant. 2020 Sep 16. pii: 10.1038/s41409-020-01041.
    PubMed    


  132. GIEBEL S, Labopin M, Sobczyk-Kruszelnicka M, Stelljes M, et al
    Total body irradiation + fludarabine compared to busulfan + fludarabine as "reduced-toxicity conditioning" for patients with acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation in first complete remission: a study by the
    Bone Marrow Transplant. 2020 Sep 5. pii: 10.1038/s41409-020-01050.
    PubMed     Abstract available


  133. JIANG S, Fan Y, Fang Y, Hou C, et al
    The role of EVI1 gene quantification in AML patients with 11q23/MLL rearrangement after allogeneic hematopoietic stem cell transplantation.
    Bone Marrow Transplant. 2020 Sep 5. pii: 10.1038/s41409-020-01048.
    PubMed     Abstract available


  134. BARON F, Labopin M, Blaise D, Itala-Remes M, et al
    Better leukemia-free survival with allogeneic than with autologous HCT in AML patients with isolated trisomy 8: a study from the ALWP of the EBMT.
    Bone Marrow Transplant. 2020 Sep 4. pii: 10.1038/s41409-020-01051.
    PubMed     Abstract available


    August 2020
  135. MURANUSHI H, Shindo T, Hishizawa M, Tokunaga M, et al
    Correction: GVHD-free, relapse-free survival provides novel clues for optimizing allogeneic-HSCT for adult T-cell leukemia/lymphoma.
    Bone Marrow Transplant. 2020 Aug 25. pii: 10.1038/s41409-020-01037.
    PubMed     Abstract available


  136. LU X, Tang LV, Wang HF, You Y, et al
    The great challenge of managing recipients of hematopoietic stem cell transplantation combined with COVID-19.
    Bone Marrow Transplant. 2020 Aug 25. pii: 10.1038/s41409-020-01035.
    PubMed    


  137. SCHETELIG J, Hoek J, Stilgenbauer S, Middeke JM, et al
    Allogeneic hematopoietic cell transplantation for patients with TP53 mutant or deleted chronic lymphocytic leukemia: Results of a prospective observational study.
    Bone Marrow Transplant. 2020 Aug 16. pii: 10.1038/s41409-020-01013.
    PubMed    


  138. YANADA M, Konuma T, Mizuno S, Saburi M, et al
    Predicting non-relapse mortality following allogeneic hematopoietic cell transplantation during first remission of acute myeloid leukemia.
    Bone Marrow Transplant. 2020 Aug 14. pii: 10.1038/s41409-020-01032.
    PubMed     Abstract available


  139. KAWAHARA Y, Morimoto A, Inagaki J, Koh K, et al
    Unrelated cord blood transplantation with myeloablative conditioning for pediatric acute lymphoblastic leukemia in remission: prognostic factors.
    Bone Marrow Transplant. 2020 Aug 11. pii: 10.1038/s41409-020-01019.
    PubMed     Abstract available


  140. FUJIMOTO A, Ishida F, Izutsu K, Yamasaki S, et al
    Allogeneic stem cell transplantation for patients with aggressive NK-cell leukemia.
    Bone Marrow Transplant. 2020 Aug 10. pii: 10.1038/s41409-020-01009.
    PubMed     Abstract available


  141. EL-HARASIS MA, Hefazi M, Julakanti R, Hogan WJ, et al
    Cardiovascular outcomes in patients receiving myeloablative vs. reduced intensity conditioning prior to allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia.
    Bone Marrow Transplant. 2020 Aug 8. pii: 10.1038/s41409-020-01021.
    PubMed    


  142. MCCAUGHAN G, Ma D, Moore J
    Two cases of successful autologous stem cell transplantation in patients with multiple myeloma and concurrent chronic myeloid leukaemia.
    Bone Marrow Transplant. 2020 Aug 8. pii: 10.1038/s41409-020-01025.
    PubMed    


  143. NAJIMA Y, Sadato D, Harada Y, Oboki K, et al
    Prognostic impact of TP53 mutation, monosomal karyotype, and prior myeloid disorder in nonremission acute myeloid leukemia at allo-HSCT.
    Bone Marrow Transplant. 2020 Aug 5. pii: 10.1038/s41409-020-01016.
    PubMed     Abstract available


  144. DALLE JH, Balduzzi A, Bader P, Pieczonka A, et al
    The impact of donor type on the outcome of pediatric patients with very high risk acute lymphoblastic leukemia. A study of the ALL SCT 2003 BFM-SG and 2007-BFM-International SG.
    Bone Marrow Transplant. 2020 Aug 4. pii: 10.1038/s41409-020-01014.
    PubMed     Abstract available


  145. SHI J, Cao L, Luo Y, Zhao Y, et al
    Maintenance sorafenib is superior to prophylactic donor lymphocyte infusion at improving the prognosis of acute myeloid leukemia with FMS-like tyrosine kinase 3 internal tandem duplication after allogeneic hematopoietic stem cell transplantation.
    Bone Marrow Transplant. 2020 Aug 4. pii: 10.1038/s41409-020-01015.
    PubMed    


    July 2020
  146. MIZUNO S, Yanada M, Kawamura K, Masuko M, et al
    Allogeneic hematopoietic cell transplantation efficacy in patients with Philadelphia chromosome-positive acute myeloid leukemia in complete remission.
    Bone Marrow Transplant. 2020 Jul 31. pii: 10.1038/s41409-020-01011.
    PubMed     Abstract available


  147. NAGLER A, Baron F, Labopin M, Polge E, et al
    Measurable residual disease (MRD) testing for acute leukemia in EBMT transplant centers: a survey on behalf of the ALWP of the EBMT.
    Bone Marrow Transplant. 2020 Jul 28. pii: 10.1038/s41409-020-01005.
    PubMed     Abstract available


  148. MURANUSHI H, Shindo T, Hishizawa M, Tokunaga M, et al
    GVHD-free, relapse-free survival provides novel clues for optimizing allogeneic-HSCT for adult T-cell leukemia/lymphoma.
    Bone Marrow Transplant. 2020 Jul 14. pii: 10.1038/s41409-020-00996.
    PubMed     Abstract available


  149. DEBUREAUX PE, Sicre de Fontbrune F, Bonfim C, Dalle JH, et al
    FLAG-sequential regimen followed by bone marrow transplantation for myelodysplastic syndrome or acute leukemia in patients with Fanconi anemia: a Franco-Brazilian study.
    Bone Marrow Transplant. 2020 Jul 10. pii: 10.1038/s41409-020-0994.
    PubMed    


    June 2020
  150. FRIETSCH JJ, Hunstig F, Wittke C, Junghanss C, et al
    Extra-medullary recurrence of myeloid leukemia as myeloid sarcoma after allogeneic stem cell transplantation: impact of conditioning intensity.
    Bone Marrow Transplant. 2020 Jun 30. pii: 10.1038/s41409-020-0984.
    PubMed     Abstract available


  151. GU B, Shi BY, Zhang X, Zhou SY, et al
    Allogeneic haematopoietic stem cell transplantation improves outcome of adults with relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia entering remission following CD19 chimeric antigen receptor T cells.
    Bone Marrow Transplant. 2020 Jun 24. pii: 10.1038/s41409-020-0982.
    PubMed     Abstract available


  152. NAGLER A, Dholaria B, Labopin M, Bruno B, et al
    The outcome of two or more HLA loci mismatched unrelated donor hematopoietic cell transplantation for acute leukemia: an ALWP of the EBMT study.
    Bone Marrow Transplant. 2020 Jun 19. pii: 10.1038/s41409-020-0974.
    PubMed     Abstract available


  153. NIU A, McDougal A, Ning B, Safa F, et al
    COVID-19 in allogeneic stem cell transplant: high false-negative probability and role of CRISPR and convalescent plasma.
    Bone Marrow Transplant. 2020 Jun 15. pii: 10.1038/s41409-020-0972.
    PubMed    


  154. BRISSOT E, Labopin M, Baron F, Bazarbachi A, et al
    Management of patients with acute leukemia during the COVID-19 outbreak: practical guidelines from the acute leukemia working party of the European Society for Blood and Marrow Transplantation.
    Bone Marrow Transplant. 2020 Jun 11. pii: 10.1038/s41409-020-0970.
    PubMed    


  155. VAN ENS D, Mousset CM, Hutten TJA, van der Waart AB, et al
    PD-L1 siRNA-mediated silencing in acute myeloid leukemia enhances anti-leukemic T cell reactivity.
    Bone Marrow Transplant. 2020 Jun 11. pii: 10.1038/s41409-020-0966.
    PubMed     Abstract available


  156. NUNEZ-TORRON C, Garcia-Gutierrez V, Tenorio-Nunez MC, Moreno-Jimenez G, et al
    Poor outcome in patients with acute leukemia on intensive chemotherapy and COVID-19.
    Bone Marrow Transplant. 2020 Jun 4. pii: 10.1038/s41409-020-0961.
    PubMed    


    May 2020
  157. AKAHOSHI Y, Nishiwaki S, Arai Y, Harada K, et al
    Reduced-intensity conditioning is a reasonable alternative for Philadelphia chromosome-positive acute lymphoblastic leukemia among elderly patients who have achieved negative minimal residual disease: a report from the Adult Acute Lymphoblastic Leukem
    Bone Marrow Transplant. 2020 May 23. pii: 10.1038/s41409-020-0951.
    PubMed     Abstract available


  158. SHOUVAL R, Labopin M, Bomze D, Baerlocher GM, et al
    Risk stratification using FLT3 and NPM1 in acute myeloid leukemia patients autografted in first complete remission.
    Bone Marrow Transplant. 2020 May 10. pii: 10.1038/s41409-020-0936.
    PubMed     Abstract available


  159. ROBESOVA B, Drncova M, Folta A, Krejci M, et al
    Donor-derived DNA variability in fingernails of acute myeloid leukemia patients after allogeneic hematopoietic stem cell transplantation detected by direct PCR.
    Bone Marrow Transplant. 2020 May 9. pii: 10.1038/s41409-020-0938.
    PubMed    


  160. COOPERRIDER JH, Fulton N, Artz AS, Larson RA, et al
    Phase I trial of maintenance selinexor after allogeneic hematopoietic stem cell transplantation for patients with acute myeloid leukemia and myelodysplastic syndrome.
    Bone Marrow Transplant. 2020 May 6. pii: 10.1038/s41409-020-0925.
    PubMed    


  161. REES MJ, Spencer A, Browett P, Alvaro F, et al
    High rate of durable remissions post autologous stem cell transplantation for core-binding factor acute myeloid leukaemia in second complete remission.
    Bone Marrow Transplant. 2020 May 6. pii: 10.1038/s41409-020-0924.
    PubMed    


  162. PERIC Z, Labopin M, Peczynski C, Polge E, et al
    Comparison of reduced-intensity conditioning regimens in patients with acute lymphoblastic leukemia >45 years undergoing allogeneic stem cell transplantation-a retrospective study by the Acute Leukemia Working Party of EBMT.
    Bone Marrow Transplant. 2020 May 2. pii: 10.1038/s41409-020-0878.
    PubMed     Abstract available


    March 2020
  163. KANDA J, Umeda K, Kato K, Murata M, et al
    Effect of graft-versus-host disease on outcomes after pediatric single cord blood transplantation.
    Bone Marrow Transplant. 2020 Mar 11. pii: 10.1038/s41409-020-0853.
    PubMed     Abstract available


    January 2020
  164. WETHMAR K, Matern S, Esseling E, Angenendt L, et al
    Monitoring minimal residual/relapsing disease after allogeneic haematopoietic stem cell transplantation in adult patients with acute lymphoblastic leukaemia.
    Bone Marrow Transplant. 2020 Jan 30. pii: 10.1038/s41409-020-0801.
    PubMed     Abstract available


    September 2019
  165. AMBERGE S, Kramer M, Schrottner P, Heidrich K, et al
    Clostridium Difficile infections in patients with AML or MDS undergoing allogeneic hematopoietic stem cell transplantation identify high risk for adverse outcome.
    Bone Marrow Transplant. 2019 Sep 18. pii: 10.1038/s41409-019-0678.
    PubMed     Abstract available


    August 2019
  166. STYCZYNSKI J, Tridello G, Koster L, Iacobelli S, et al
    Death after hematopoietic stem cell transplantation: changes over calendar year time, infections and associated factors.
    Bone Marrow Transplant. 2019 Aug 27. pii: 10.1038/s41409-019-0624.
    PubMed     Abstract available


    May 2019
  167. BABOR F, Peters C, Manser AR, Glogova E, et al
    Presence of centromeric but absence of telomeric group B KIR haplotypes in stem cell donors improve leukaemia control after HSCT for childhood ALL.
    Bone Marrow Transplant. 2019 May 14. pii: 10.1038/s41409-019-0543.
    PubMed     Abstract available


    February 2019
  168. ZHANG YY, Mo XD, Zhang XH, Xu LP, et al
    FLT3 internal tandem duplication does not impact prognosis after haploidentical allogeneic hematopoietic stem cell transplantation in AML patients.
    Bone Marrow Transplant. 2019 Feb 1. pii: 10.1038/s41409-019-0456.
    PubMed     Abstract available


    December 2018
  169. ALATRASH G, Kidwell KM, Thall PF, Di Stasi A, et al
    Reduced intensity vs. myeloablative conditioning with fludarabine and PK-guided busulfan in allogeneic stem cell transplantation for patients with AML/MDS.
    Bone Marrow Transplant. 2018 Dec 10. pii: 10.1038/s41409-018-0405.
    PubMed     Abstract available


  170. BONDANZA A, Ruggeri L, Noviello M, Eikema DJ, et al
    Beneficial role of CD8+ T-cell reconstitution after HLA-haploidentical stem cell transplantation for high-risk acute leukaemias: results from a clinico-biological EBMT registry study mostly in the T-cell-depleted setting.
    Bone Marrow Transplant. 2018 Dec 7. pii: 10.1038/s41409-018-0351.
    PubMed     Abstract available


    November 2018
  171. GERULL S, Tschan-Plessl A, Mathew R, Nair G, et al
    Late relapse after stopping sorafenib in allogeneic hematopoietic stem cell transplant recipients.
    Bone Marrow Transplant. 2018 Nov 6. pii: 10.1038/s41409-018-0376.
    PubMed    


    October 2018
  172. SHAH MV, Saliba RM, Rondon G, Chen J, et al
    Pilot study using post-transplant cyclophosphamide (PTCy), tacrolimus and mycophenolate GVHD prophylaxis for older patients receiving 10/10 HLA-matched unrelated donor hematopoietic stem cell transplantation.
    Bone Marrow Transplant. 2018 Oct 18. pii: 10.1038/s41409-018-0367.
    PubMed     Abstract available


    August 2018
  173. LIN RJ, Elko TA, Perales MA, Alexander K, et al
    End-of-life care for older AML patients relapsing after allogeneic stem cell transplant at a dedicated cancer center.
    Bone Marrow Transplant. 2018 Aug 22. pii: 10.1038/s41409-018-0311.
    PubMed     Abstract available


  174. GUNES G, Goker H, Demiroglu H, Malkan UY, et al
    Extramedullary relapses of acute leukemias after allogeneic hematopoietic stem cell transplantation: clinical features, cumulative incidence, and risk factors.
    Bone Marrow Transplant. 2018 Aug 16. pii: 10.1038/s41409-018-0303.
    PubMed     Abstract available


    June 2018
  175. TOMIZAWA D, Yoshida M, Kondo T, Miyamura T, et al
    Allogeneic hematopoietic stem cell transplantation for children and adolescents with high-risk cytogenetic AML: distinctly poor outcomes of FUS-ERG-positive cases.
    Bone Marrow Transplant. 2018 Jun 29. pii: 10.1038/s41409-018-0273.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Leukemia is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: